Equity Profile

COGT

Cogent Biosciences, Inc.

Health CareBiotechnology$6.4B

Nov3Wed

Pre-Earnings Brief

UpcomingQ4-2024After Close5:00 PM EDT

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing treatments for genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenue.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market traction and ability to scale its operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

COGT Q4-2024 Earnings Preview

Context

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing treatments for genetic diseases. With a market cap of $6 billion, it plays a significant role in the healthcare sector, particularly in addressing unmet medical needs through innovative therapies.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-13.59%

Avg Stock Reaction

+3.32%

Last Quarter Recap

In Q3-2024, Cogent reported an EPS of -$0.64, missing estimates by 17%. The stock experienced a slight decline of 0.19% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed ahead of the earnings report, with no analyst estimates available to guide sentiment.

Bull Case

If Cogent can show better-than-expected EPS and revenue growth, it could signal strong demand for its products and a positive outlook for future quarters.

Bear Case

Conversely, continued losses and lack of revenue growth could raise concerns about the company's financial health and its ability to deliver on its promises.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous estimates?

Given the company's recent history of missing EPS estimates, this will be a crucial indicator of financial performance and investor sentiment.

What is the outlook for revenue growth moving forward?

Revenue growth is essential for assessing the company's ability to sustain operations and invest in future product development.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a turnaround in Cogent's financial performance, especially if there are signs of improved operational efficiency.

Supporting Evidence

Despite recent EPS misses, the stock has shown resilience with positive reactions in the days following earnings.

The options market is pricing a move of 10.4%, suggesting that traders expect significant volatility, which could indicate underlying opportunities.

Historical trends show that even with misses, the stock has often rebounded, indicating potential for recovery.

Key Risk

If the EPS comes in better than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Cogent can turn around its recent trend of EPS misses and demonstrate revenue growth.

Bull Confirmed If

An EPS improvement to -$0.50 or better, along with positive revenue growth, would confirm the bull case.

Bear Confirmed If

An EPS of -$0.70 or worse would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±10.4%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move of about 10.4%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±10.4% while COGT has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

34.5%

Calls (74K)P/C Ratio: 0.10Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

103.29%

of float

Insider

0.29%

of float

Holders

362

institutions

Top Holders· as of Dec 2025

FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cogent beats expectations, history suggests a potential stock increase of around 2.45%, confirming a positive outlook.

In-Line / Cautious

If results are in line but cautious, the stock may react modestly, reflecting uncertainty in future guidance.

Miss

Should the company miss expectations, history suggests a potential decline of about 3.44%, raising concerns about its financial trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or clinical trial results.
2Management's commentary on cost management and operational efficiencies.
3Guidance on revenue expectations for the next quarter.
4Insights into market demand for Cogent's therapies.
5Any strategic partnerships or collaborations that could enhance growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Nov1

AEISReported

Advanced Energy Industries, Inc.

RecapView

Nov1

CNAReported

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing treatments for genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenue.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market traction and ability to scale its operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

COGT Q4-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-13.59%

Avg Stock Reaction

+3.32%

Last Quarter Recap

In Q3-2024, Cogent reported an EPS of -$0.64, missing estimates by 17%. The stock experienced a slight decline of 0.19% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed ahead of the earnings report, with no analyst estimates available to guide sentiment.

Bull Case

If Cogent can show better-than-expected EPS and revenue growth, it could signal strong demand for its products and a positive outlook for future quarters.

Bear Case

Conversely, continued losses and lack of revenue growth could raise concerns about the company's financial health and its ability to deliver on its promises.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous estimates?

Given the company's recent history of missing EPS estimates, this will be a crucial indicator of financial performance and investor sentiment.

What is the outlook for revenue growth moving forward?

Revenue growth is essential for assessing the company's ability to sustain operations and invest in future product development.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a turnaround in Cogent's financial performance, especially if there are signs of improved operational efficiency.

Supporting Evidence

Despite recent EPS misses, the stock has shown resilience with positive reactions in the days following earnings.

The options market is pricing a move of 10.4%, suggesting that traders expect significant volatility, which could indicate underlying opportunities.

Historical trends show that even with misses, the stock has often rebounded, indicating potential for recovery.

Key Risk

If the EPS comes in better than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Cogent can turn around its recent trend of EPS misses and demonstrate revenue growth.

Bull Confirmed If

An EPS improvement to -$0.50 or better, along with positive revenue growth, would confirm the bull case.

Bear Confirmed If

An EPS of -$0.70 or worse would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±10.4%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move of about 10.4%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±10.4% while COGT has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

34.5%

Calls (74K)P/C Ratio: 0.10Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

103.29%

of float

Insider

0.29%

of float

Holders

362

institutions

Top Holders· as of Dec 2025

FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cogent beats expectations, history suggests a potential stock increase of around 2.45%, confirming a positive outlook.

In-Line / Cautious

If results are in line but cautious, the stock may react modestly, reflecting uncertainty in future guidance.

Miss

Should the company miss expectations, history suggests a potential decline of about 3.44%, raising concerns about its financial trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or clinical trial results.
2Management's commentary on cost management and operational efficiencies.
3Guidance on revenue expectations for the next quarter.
4Insights into market demand for Cogent's therapies.
5Any strategic partnerships or collaborations that could enhance growth.